AR035327A1 - Agonistas no peptidicos de la vasopresina, selectivos para los receptores del subtipo v2; uso de dichos compuestos en la preparacion de composiciones farmaceuticas utilizables en el tratamiento de enfermedades del hombre, caracterizadas por poliuria; dichas composiciones y metodos para el tratamient - Google Patents
Agonistas no peptidicos de la vasopresina, selectivos para los receptores del subtipo v2; uso de dichos compuestos en la preparacion de composiciones farmaceuticas utilizables en el tratamiento de enfermedades del hombre, caracterizadas por poliuria; dichas composiciones y metodos para el tratamientInfo
- Publication number
- AR035327A1 AR035327A1 ARP010100035A ARP010100035A AR035327A1 AR 035327 A1 AR035327 A1 AR 035327A1 AR P010100035 A ARP010100035 A AR P010100035A AR P010100035 A ARP010100035 A AR P010100035A AR 035327 A1 AR035327 A1 AR 035327A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- independently selected
- compounds
- pharmaceutical compositions
- vasopresine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000004880 Polyuria Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 208000008967 Enuresis Diseases 0.000 abstract 1
- 208000003450 Neurogenic Diabetes Insipidus Diseases 0.000 abstract 1
- 102000004136 Vasopressin Receptors Human genes 0.000 abstract 1
- 108090000643 Vasopressin Receptors Proteins 0.000 abstract 1
- 229940083335 Vasopressin agonist Drugs 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000002686 anti-diuretic effect Effects 0.000 abstract 1
- 229940124538 antidiuretic agent Drugs 0.000 abstract 1
- 150000001538 azepines Chemical class 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 208000028235 central diabetes insipidus Diseases 0.000 abstract 1
- 201000010064 diabetes insipidus Diseases 0.000 abstract 1
- 201000005119 neurohypophyseal diabetes insipidus Diseases 0.000 abstract 1
- 206010029446 nocturia Diseases 0.000 abstract 1
- 208000005346 nocturnal enuresis Diseases 0.000 abstract 1
- 239000003805 procoagulant Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen y reivindican compuestos novedosos que responden a la fórmula general (1), en donde A es un derivado de azepina bicíclico o tricíclico seleccionado entre las fórmulas generales (2) a (7); A1, A4, A7 y A10 son cada uno independientemente seleccionados entre CH2, O y NR8; A2, A3, A9, A11, A14 y A15 son cada uno independientemente seleccionados entre CH y N; A5 es un enlace covalente y A6 es S, o A5 es N=CH y A6 es un enlace covalente; A8 y A12 son cada uno independientemente seleccionados entre NH y S; A16 y A17 son ambos CH2, o uno entre A16 y A17 es CH2 y el otro es seleccionado entre O, SOx y NR8; V1 y V2 son ambos H, OMe o F, o uno entre V1 y V2 es Br, Cl, F, OH, OMe, OBn, OPh, O-acilo, N3, NH2, NHBn o NH-acilo y el otro es H, o V1 y V2 juntos son =O, -O(CH2)pO- o -S(CH2)pS-; W1 es O ó S; X1 y X2 son ambos H, o juntos son =O ó =S; Y es OR5 o NR6R7; Z es S o -CH=CH-; R1, R2, R3 y R4 son independientemente seleccionados entre H, alquilo inferior, alquiloxi inferior, F, Cl y Br; R6 y R7 son independientemente seleccionados entre H y alquilo inferior, o juntos son -(CH2)n-; R8 es H o alquilo inferior; n = 3, 4, 5 ó 6; p es 2 ó 3; y x es 0, 1 ó 2. Los compuestos son agonistas en el receptor de vasopresina V2 y son útiles como antidiuréticos y pro-coagulantes. La presente comprende además composiciones farmacéuticas que incorporan dichos agonistas de vasopresina, en donde dichas composiciones son particularmente útiles en el tratamiento de diabetes insípida central, enuresis nocturna y nocturia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0000079.4A GB0000079D0 (en) | 2000-01-05 | 2000-01-05 | Novel antidiuretic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035327A1 true AR035327A1 (es) | 2004-05-12 |
Family
ID=9883168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100035A AR035327A1 (es) | 2000-01-05 | 2001-01-04 | Agonistas no peptidicos de la vasopresina, selectivos para los receptores del subtipo v2; uso de dichos compuestos en la preparacion de composiciones farmaceuticas utilizables en el tratamiento de enfermedades del hombre, caracterizadas por poliuria; dichas composiciones y metodos para el tratamient |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US7074781B2 (es) |
| EP (1) | EP1248784B1 (es) |
| JP (2) | JP3869723B2 (es) |
| KR (1) | KR100605466B1 (es) |
| CN (1) | CN1183129C (es) |
| AR (1) | AR035327A1 (es) |
| AT (1) | ATE366730T1 (es) |
| AU (1) | AU777538B2 (es) |
| BR (1) | BR0107414B1 (es) |
| CA (1) | CA2396277C (es) |
| CY (1) | CY1108034T1 (es) |
| CZ (1) | CZ303444B6 (es) |
| DE (1) | DE60129298T2 (es) |
| DK (1) | DK1248784T3 (es) |
| EE (1) | EE200200367A (es) |
| ES (1) | ES2288923T3 (es) |
| GB (1) | GB0000079D0 (es) |
| HK (1) | HK1046910B (es) |
| HR (1) | HRP20020481B1 (es) |
| HU (1) | HU229937B1 (es) |
| IL (1) | IL149528A0 (es) |
| MX (1) | MXPA02006546A (es) |
| MY (1) | MY140467A (es) |
| NO (1) | NO322571B1 (es) |
| NZ (1) | NZ518803A (es) |
| PL (1) | PL211341B1 (es) |
| PT (1) | PT1248784E (es) |
| RU (1) | RU2259367C2 (es) |
| SI (1) | SI1248784T1 (es) |
| SK (1) | SK287005B6 (es) |
| UA (1) | UA73152C2 (es) |
| UY (1) | UY26521A1 (es) |
| WO (1) | WO2001049682A1 (es) |
| ZA (1) | ZA200205180B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5803659A (en) | 1995-12-08 | 1998-09-08 | Chattey; Nigel | Modular caissons for use in constructing, expanding and modernizing ports and harbors. |
| US7138393B2 (en) | 1998-07-24 | 2006-11-21 | Wyeth | Biologically active vasopressin agonist metabolites |
| GB0000079D0 (en) * | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| WO2001074769A1 (en) * | 2000-03-27 | 2001-10-11 | Applied Research Systems Ars Holding N.V. | Pharmaceutically active pyrrolidine derivatives as bax inhibitors |
| EE200200555A (et) * | 2000-03-27 | 2004-06-15 | Applied Research Systems Ars Holding N.V. | Farmatseutiliselt aktiivsed pürrolidiini derivaadid |
| GB0015601D0 (en) * | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
| GB0115515D0 (en) * | 2001-06-25 | 2001-08-15 | Ferring Bv | Oxytocin agonisys |
| GB0210397D0 (en) * | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| ATE512951T1 (de) * | 2003-04-28 | 2011-07-15 | Astellas Pharma Inc | 4,4-difluor-1,2,3,4-tetrahydro-5h-1- benzazepinderivat oder salz davon |
| PT1530967E (pt) * | 2003-11-13 | 2006-09-29 | Ferring Bv | Embalagem blister e uma forma de dosagem solida que compreende desmopressina. |
| JP4943858B2 (ja) * | 2004-11-17 | 2012-05-30 | キッセイ薬品工業株式会社 | 芳香族アミド誘導体、それを含有する医薬組成物およびそれらの医薬用途 |
| EP1867639A1 (en) * | 2005-03-25 | 2007-12-19 | Kissei Pharmaceutical Co., Ltd. | Urea derivative, medicinal composition containing the same, and medicinal use of these |
| WO2007052517A1 (ja) * | 2005-10-31 | 2007-05-10 | Sumitomo Chemical Company, Limited | ヒドロキシ－２－ピロリジンカルボキシアミド化合物の製法 |
| WO2008038600A1 (en) * | 2006-09-25 | 2008-04-03 | Kissei Pharmaceutical Co., Ltd. | 1,4-benzodiazepine derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes |
| NZ580801A (en) * | 2007-05-10 | 2012-09-28 | Bristol Myers Squibb Co | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| RU2472539C2 (ru) | 2007-08-06 | 2013-01-20 | Аллерган, Инк. | Способы и устройства для доставки препарата десмопрессина |
| ES2710454T3 (es) * | 2008-05-21 | 2019-04-25 | Ferring Bv | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nocturia |
| US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
| US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
| GB201005623D0 (en) * | 2010-04-01 | 2010-05-19 | Vantia Ltd | New polymorph |
| GB201105537D0 (en) * | 2011-03-31 | 2011-05-18 | Vantia Ltd | New process |
| WO2020154581A1 (en) | 2019-01-24 | 2020-07-30 | Assia Chemical Industries Ltd | Solid state forms of fedovapagon-salicyclic acid co-crystal |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3960886A (en) * | 1968-07-03 | 1976-06-01 | Sterling Drug Inc. | Substituted N-arylanilines |
| CH599752A5 (es) | 1973-04-18 | 1978-05-31 | Ciba Geigy Ag | |
| CA1047490A (en) * | 1973-04-18 | 1979-01-30 | Friedrich Karrer | Ethers |
| DE2355454A1 (de) | 1973-11-07 | 1976-10-07 | Paul Geisslinger | Lochmaschine |
| JPH0641455B2 (ja) | 1984-12-10 | 1994-06-01 | 日産化学工業株式会社 | ピリダジノン誘導体 |
| US5753677A (en) * | 1989-10-20 | 1998-05-19 | Otsuka Pharmaceutical Co., Ltd. | Benzoheterocyclic compounds |
| EP0450097B1 (en) | 1989-10-20 | 1996-04-24 | Otsuka Pharmaceutical Co., Ltd. | Benzoheterocyclic compounds |
| CA2066104C (en) * | 1991-04-19 | 2003-05-27 | Hidenori Ogawa | Benzazepine derivatives as vasopressin antagonists |
| JPH05320135A (ja) | 1992-05-19 | 1993-12-03 | Yamanouchi Pharmaceut Co Ltd | テトラヒドロベンズアゼピン誘導体 |
| AU657431B2 (en) * | 1992-08-20 | 1995-03-09 | Otsuka Pharmaceutical Co., Ltd. | Benzoheterocyclic compounds as oxytocin and vasopressin antagonists |
| TW270927B (es) | 1992-10-16 | 1996-02-21 | Otsuka Pharma Co Ltd | |
| WO1994012476A1 (fr) * | 1992-11-25 | 1994-06-09 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de benzanilide |
| WO1994020473A1 (fr) * | 1993-03-11 | 1994-09-15 | Yamanouchi Pharmaceutical Co., Ltd. | Compose avec action antagoniste de la vasopressine |
| GB9307527D0 (en) | 1993-04-13 | 1993-06-02 | Fujisawa Pharmaceutical Co | New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
| US5843952A (en) * | 1993-07-29 | 1998-12-01 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5516774A (en) | 1993-07-29 | 1996-05-14 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| US5968930A (en) * | 1993-07-29 | 1999-10-19 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| US5760031A (en) * | 1993-07-29 | 1998-06-02 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US6403577B1 (en) * | 1993-11-17 | 2002-06-11 | Eli Lilly And Company | Hexamethyleneiminyl tachykinin receptor antagonists |
| FI1215U1 (fi) * | 1993-12-03 | 1994-02-21 | Valmet Paper Machinery Inc | Anlaeggning i samband med styrningen av en vira |
| FR2716194B1 (fr) * | 1994-02-14 | 1996-05-31 | Sanofi Elf | Dérivés de 3-acylamino-5-phényl-1,4-benzodiazépin-2-one polysubstitués, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
| EP0707757B1 (en) * | 1994-05-06 | 1999-12-29 | Koninklijke Philips Electronics N.V. | Microwave transmission system |
| PT765314E (pt) | 1994-06-15 | 2003-09-30 | Otsuka Pharma Co Ltd | Derivados benzo-heterociclicos uteis como moduladores da vasopressina ou da oxitocina |
| JP2926335B2 (ja) | 1997-06-13 | 1999-07-28 | 大塚製薬株式会社 | 医薬組成物 |
| SI1000062T1 (en) * | 1997-07-30 | 2004-12-31 | Wyeth | Tricyclic vasopressin agonists |
| CA2297407A1 (en) * | 1997-07-30 | 1999-02-11 | American Home Products Corporation | Tricyclic vasopressin agonists |
| JP2002527438A (ja) * | 1998-10-09 | 2002-08-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ４，５−ジヒドロ−イソオキサゾール誘導体及びそれらの製薬学的使用 |
| GB2355454A (en) | 1999-10-20 | 2001-04-25 | Ferring Bv | Antidiuretic agents |
| GB0000079D0 (en) | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| GB0015601D0 (en) * | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
| DE10033337A1 (de) | 2000-07-08 | 2002-01-17 | Boehringer Ingelheim Pharma | Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| GB0120051D0 (en) | 2001-08-16 | 2001-10-10 | Ferring Bv | Oxytocin agonists |
| GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| EP1449844A1 (en) * | 2003-02-14 | 2004-08-25 | Ferring B.V. | benzamide derivatives as oxytocin agonists and vasopressin antagonists |
| EP1627876A1 (en) * | 2004-08-20 | 2006-02-22 | Ferring B.V. | Heterocyclic condensed compounds useful as antidiuretic agents |
| US7341963B2 (en) * | 2005-05-17 | 2008-03-11 | Milliken & Company | Non-woven material with barrier skin |
-
2000
- 2000-01-05 GB GBGB0000079.4A patent/GB0000079D0/en not_active Ceased
-
2001
- 2001-01-04 ES ES01900169T patent/ES2288923T3/es not_active Expired - Lifetime
- 2001-01-04 PT PT01900169T patent/PT1248784E/pt unknown
- 2001-01-04 AT AT01900169T patent/ATE366730T1/de active
- 2001-01-04 UY UY26521A patent/UY26521A1/es not_active IP Right Cessation
- 2001-01-04 MY MYPI20010027A patent/MY140467A/en unknown
- 2001-01-04 DE DE60129298T patent/DE60129298T2/de not_active Expired - Lifetime
- 2001-01-04 JP JP2001550222A patent/JP3869723B2/ja not_active Expired - Fee Related
- 2001-01-04 NZ NZ518803A patent/NZ518803A/xx not_active IP Right Cessation
- 2001-01-04 EP EP01900169A patent/EP1248784B1/en not_active Expired - Lifetime
- 2001-01-04 KR KR1020027006382A patent/KR100605466B1/ko not_active Expired - Fee Related
- 2001-01-04 WO PCT/GB2001/000023 patent/WO2001049682A1/en not_active Ceased
- 2001-01-04 CZ CZ20022305A patent/CZ303444B6/cs not_active IP Right Cessation
- 2001-01-04 PL PL355808A patent/PL211341B1/pl unknown
- 2001-01-04 CA CA2396277A patent/CA2396277C/en not_active Expired - Lifetime
- 2001-01-04 AR ARP010100035A patent/AR035327A1/es active IP Right Grant
- 2001-01-04 SK SK911-2002A patent/SK287005B6/sk not_active IP Right Cessation
- 2001-01-04 HR HR20020481A patent/HRP20020481B1/xx not_active IP Right Cessation
- 2001-01-04 IL IL14952801A patent/IL149528A0/xx active IP Right Grant
- 2001-01-04 DK DK01900169T patent/DK1248784T3/da active
- 2001-01-04 EE EEP200200367A patent/EE200200367A/xx unknown
- 2001-01-04 RU RU2002120798/04A patent/RU2259367C2/ru not_active IP Right Cessation
- 2001-01-04 CN CNB018031323A patent/CN1183129C/zh not_active Expired - Fee Related
- 2001-01-04 SI SI200130766T patent/SI1248784T1/sl unknown
- 2001-01-04 US US10/130,749 patent/US7074781B2/en not_active Expired - Lifetime
- 2001-01-04 HK HK02108525.5A patent/HK1046910B/en not_active IP Right Cessation
- 2001-01-04 BR BRPI0107414-8A patent/BR0107414B1/pt not_active IP Right Cessation
- 2001-01-04 AU AU23846/01A patent/AU777538B2/en not_active Ceased
- 2001-01-04 HU HU0203917A patent/HU229937B1/hu not_active IP Right Cessation
- 2001-01-04 MX MXPA02006546A patent/MXPA02006546A/es active IP Right Grant
- 2001-04-01 UA UA2002075517A patent/UA73152C2/uk unknown
-
2002
- 2002-06-27 NO NO20023137A patent/NO322571B1/no not_active IP Right Cessation
- 2002-06-27 ZA ZA200205180A patent/ZA200205180B/en unknown
-
2005
- 2005-12-20 JP JP2005366100A patent/JP3813629B2/ja not_active Expired - Fee Related
-
2006
- 2006-03-09 US US11/370,861 patent/US7560454B2/en not_active Expired - Fee Related
-
2007
- 2007-10-04 CY CY20071101261T patent/CY1108034T1/el unknown
-
2008
- 2008-06-23 US US12/213,651 patent/US20080261951A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035327A1 (es) | Agonistas no peptidicos de la vasopresina, selectivos para los receptores del subtipo v2; uso de dichos compuestos en la preparacion de composiciones farmaceuticas utilizables en el tratamiento de enfermedades del hombre, caracterizadas por poliuria; dichas composiciones y metodos para el tratamient | |
| ES2401892T3 (es) | Compuestos morfinanos | |
| UY25142A1 (es) | Antagonistas del receptor ccr-3 | |
| PA8472301A1 (es) | Derivados de isotiazol utiles como agentes anticancerosos | |
| GT199800180A (es) | Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos. | |
| SV1999000141A (es) | Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos ref. pc10411abcz/bb | |
| PA8494101A1 (es) | Derivados heterociclicos utiles como agentes anticancerosos | |
| DOP2001000170A (es) | Derivados de tiofeno utiles como agentes anticancesoros | |
| PA8546601A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
| PE20081557A1 (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
| ES2111650T3 (es) | Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p. | |
| HN2011001358A (es) | Moduladores de aril metil benzoquinazolina alostericos positivos del receptor m1 | |
| EA200970928A1 (ru) | Антагонисты рецептора гонадотропин-рилизин-фактора и способы их применения | |
| ATE530182T1 (de) | Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen | |
| DOP2003000624A (es) | Derivados de tropano como moduladores de ccr5 | |
| IT1250049B (it) | Composti triciclici. | |
| CA2571198A1 (en) | Progesterone receptor antagonist contraceptive regimens and kits | |
| ATE530187T1 (de) | Pharmazeutische zubereitungen mit nk1-rezeptor- antagonisten und natriumkanalblockern | |
| MX9300616A (es) | Compuestos antagonistas del receptor 5-hidroxitriptamina, proceso para su prepararcion y composicion farmaceutica que los contiene | |
| CO6430439A2 (es) | Agonistas del receptor de esfingosina -1- fosfato | |
| ES2536984T3 (es) | Compuestos de morfina | |
| AR015446A1 (es) | Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios | |
| AR050914A1 (es) | Agonista receptor de vasopresina peptidico | |
| ATE444965T1 (de) | Sich als therapeutische mittel eignende arylalkylindole mit affinität für den serotoninrezeptor, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten | |
| AR039008A1 (es) | Derivados azabiciclicos, azatriciclicos y azaespirociclicos de aminociclohexano antagonistas de los receptores nmda, 5-ht3, y nicotinico neuronal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |